Cytovance Biologics, Inc. announces Bexion Pharmaceuticals Inc. has chosen Cytovance to manufacture the protein component and active ingredient of Bexion’s first clinical compound, BXQ-350 OKLAHOMA CITY, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Cytovance Biologics, Inc. (Cytovance), a leading full-service contract development and manufacturer of mammalian and microbial biologics, today...

Biologics Dominate the Autoimmune Market but Small Molecules Still Have Some Fight Left, Says Cutting Edge Information RESEARCH TRIANGLE PARK, NC--(Marketwire - June 30, 2009) - Biological drugs are the big winners in the market for autoimmune disorders. According to "Autoimmune Market Forecast to 2014," the latest...